Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cardiol Therapeutics Inc. (CRDL) had Return on Tangible Equity of -70.75% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.04M |
|
-- |
|
-- |
|
$5.55M |
|
$-5.55M |
|
$-0.49M |
|
$-6.04M |
|
$-6.04M |
|
$-6.04M |
|
$-6.04M |
|
$-6.04M |
|
$-6.04M |
|
$-5.55M |
|
$-5.53M |
|
82.65M |
|
82.65M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$14.30M |
|
$0.12M |
|
$0.12M |
|
$14.41M |
|
$5.80M |
|
$0.08M |
|
$0.08M |
|
$5.88M |
|
$8.54M |
|
$8.54M |
|
$8.54M |
|
82.67M |
|
| Cash Flow Statement Financials | |
$-8.46M |
|
$-0.01M |
|
$0.00M |
|
$22.11M |
|
$13.15M |
|
$-8.95M |
|
$2.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.46 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-70.75% |
|
|
Return on Tangible Equity |
-70.75% |
-41.90% |
|
-70.12% |
|
$0.10 |
|
$-0.10 |
|
$-0.10 |
|